Merck KGaA sees immunotherapy drug holding its own in cancer race

FRANKFURT, June 1 (Reuters) - The head of Merck KGaA's healthcare division said she expected its cancer drug avelumab, jointly developed with Pfizer, to be among the first two or three to market in a field of immunotherapy pharmaceuticals that harness the power of the immune system in a range of cancer types.